From the Department of Hematology/Oncology for Children and Adolescents, Sapporo Hokuyu Hospital, Sapporo, Japan.
Department of Pediatrics, St. Marianna University School of Medicine Hospital, Kawasaki, Japan.
Pediatr Infect Dis J. 2018 May;37(5):447-450. doi: 10.1097/INF.0000000000001802.
Liposomal amphotericin (L-AMB) is a widely used broad-spectrum antifungal drug. Although L-AMB demonstrates better safety compared with amphotericin, renal dysfunction and hypokalemia are well-known adverse effects of L-AMB.
We analyzed 56 episodes in 40 children and adolescents who received L-AMB therapy to determine risk factors of hypokalemia.
Hypokalemia (<3.0 mEq/L continuously for more than 2 episodes) was observed in 31 of 56 episodes (55.4%). The median onset of hypokalemia was at 10 days on L-AMB (range, 3-54 days), and the median cumulative dose of L-AMB at occurrence of hypokalemia was 25 mg/kg (range, 10-167.5 mg/kg). None of the patients with hypokalemia had solid tumors, and they had significantly higher estimated glomerular filtration rates than those with normokalemia (P = 0.013). Seven of 25 (28.0%) patients in the normokalemia group and 1 of 31 (3.2%) patients in the hypokalemia group had eGFRs of <90 mL/min/1.73 m(2) (P = 0.017).
Although the reason for the association between estimated glomerular filtration rates and hypokalemia is unclear, assessing the estimated glomerular filtration rates before L-AMB administration may predict the development of hypokalemia.
脂质体两性霉素(L-AMB)是一种广泛使用的广谱抗真菌药物。虽然 L-AMB 与两性霉素相比具有更好的安全性,但肾功能障碍和低钾血症是 L-AMB 的已知不良反应。
我们分析了 40 名接受 L-AMB 治疗的儿童和青少年 56 例次中低钾血症的危险因素。
56 例次中有 31 例次(55.4%)出现低钾血症(连续 2 次以上<3.0 mEq/L)。低钾血症的中位发病时间为 L-AMB 治疗后 10 天(范围 3-54 天),发生低钾血症时 L-AMB 的累积剂量中位数为 25mg/kg(范围 10-167.5mg/kg)。发生低钾血症的患儿均无实体瘤,估计肾小球滤过率(eGFR)明显高于血钾正常的患儿(P = 0.013)。血钾正常组 25 例次中有 7 例(28.0%)和低钾血症组 31 例次中有 1 例(3.2%)eGFR <90mL/min/1.73m2(P = 0.017)。
尽管 eGFR 与低钾血症之间的关联原因尚不清楚,但在使用 L-AMB 前评估 eGFR 可能有助于预测低钾血症的发生。